Annual Report for Cline Scientific AB (publ), 556867-8238, for the period 1 January – 31 December 2023

Cline Scientific AB (publ) ("Cline" or the "Company") issues the following annual report for 2023.

The report is published at www.clinescientific.com/financial-reports

The company is listed on the Nasdaq First North Growth Market. Redeye AB is Cline Scientific's Certified Adviser. The information was submitted for publication via the contact person listed above, at 9:15 CEST on 26 May 2024.

For more information, please contact:
Patrik Sundh, CEO
Email: patrik.sundh@clinescientific.com
Phone: +46 703-585 088

Cline Scientific AB (publ)                                                
Pepparedsleden 1
AstraZeneca BioVentureHub                                               Email: info@clinescientific.com
431 53  MÖLNDAL                                                             Website: www.clinescientific.com

About Cline Scientific
Cline Scientific develops advanced cancer diagnostics and regenerative medicine treatments. Cline’s unique patented surface nanotechnology provides solutions to critical challenges for cell-based products and process in Life Science. Cline is driving two projects through to a clinical stage, StemCART - a stem cell therapy for joint repair, and CellRACE- a cancer diagnostic to predict metastasis.